AR020154A1 - Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion - Google Patents

Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion

Info

Publication number
AR020154A1
AR020154A1 ARP990103999A ARP990103999A AR020154A1 AR 020154 A1 AR020154 A1 AR 020154A1 AR P990103999 A ARP990103999 A AR P990103999A AR P990103999 A ARP990103999 A AR P990103999A AR 020154 A1 AR020154 A1 AR 020154A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
substituted
cycloalkyl
phenyl
Prior art date
Application number
ARP990103999A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR020154A1 publication Critical patent/AR020154A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Abstract

Se describen compuestos de la formula (1), donde: Z representa un cicloalquilo de 5 o 6 miembros, arilo, cicloalquilo substituido, o arilo substituido,dicho cicloalquilo, arilo, cicloalquilo substituido, o arilo substituido contienen opcionalmenteun o o más heteroátomos seleccionados de O, N o S;R1 representa hidrogeno o metilo; R2 representa hidrogeno, alquilo C1-12, arilo o aralquilo; k representa 0 o 1; n representa un numero entero de 1 a 50;X representa -O-, -N(H)-, -N(alquilo C1-6)-N(ciclo alquilo C3-8)-, -N(alquilo C1-8)(cicloalquilo C3-8), -N[(CH2CH2O)m(alquilo C1-12), arilo o aralquilo)],-CH2O-, -CH2NH-, CH2N(alquilo C1-6)-, -CH2N(cicloalquilo C3-8)-, o -alquilo C1-12-; m representa 0-12; Q representa (-CH2)p, (-CH=CH-)p, (-C:::C-)p ,(-(O)p1CH2-)p o (-CH2(O)p1)p en donde p y p1 independientemente representan un numero entero de 0 a 4; y e y independientemente representan numerosenteros de 0 a 10; R3 representa H, alquilo C1-12 de cadena recta o ramificada(opcionalmente sustitui do por fenilo, fenilo -CO-, CN, -CO alquilo C1-3-CO2alquilo C1-3, o que contiene uno o más átomos O en la cadena alquilo); alquenilo de cadena recta o ramificada C1-6 (opcionalmente substituido por fenilo,fenilo -CO, CN, -CO-alquilo C1-3, -CO2 alquil o C1-3, o que contiene uno o más átomos O en la cadena alquilo); alquenilo de cadena recta o ramificada conC1-6 o un grupo -alquilo C1-3-NR8R9, en donde R8 y R9 son independientemente H, alquilo C1-3 o juntos forman ungrupo heterocíclico con 5 o 6 m iembros, quecontiene opcionalmente otros heteroátomos seleccionados de O, N o S; R4 y R5 independientemente representan: cicloalquilo C3-8, alquilo C1-6 de cadena recta oramificada, hidrogeno, alquenilo C2-6 de cadenarecta o ramificada, arilo o aril o substituido; grupo heterocíclico o grupo heterocíclico substituido, queincluye heteroarilo y grupos heteroarilo substituidos; R6 y R7 independientemente representan O o S; con la condicion de que cuando: y e yambos representen1, k representa 1, p1 representa 0, R2 representa H o Me, R3 representa H, X representa O o NH, y Z representa fenilo; R4 y R5 ambos no representan ciclohexilo
ARP990103999A 1998-08-13 1999-08-10 Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion AR020154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
AR020154A1 true AR020154A1 (es) 2002-04-10

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103999A AR020154A1 (es) 1998-08-13 1999-08-10 Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion

Country Status (37)

Country Link
US (3) US6608069B1 (es)
EP (1) EP1104422B1 (es)
JP (3) JP3631961B2 (es)
KR (1) KR20010085369A (es)
CN (2) CN1251676C (es)
AP (1) AP1408A (es)
AR (1) AR020154A1 (es)
AT (1) ATE259810T1 (es)
AU (1) AU775819B2 (es)
BR (1) BR9913020A (es)
CA (1) CA2340350A1 (es)
CO (1) CO5130007A1 (es)
DE (1) DE69914921T2 (es)
DK (1) DK1104422T3 (es)
EA (1) EA004139B1 (es)
EE (1) EE04721B1 (es)
ES (1) ES2215399T3 (es)
GB (1) GB9817623D0 (es)
HK (1) HK1035195A1 (es)
HU (1) HUP0103637A3 (es)
ID (1) ID28723A (es)
IL (1) IL141318A0 (es)
IS (1) IS5843A (es)
MA (1) MA26673A1 (es)
MY (1) MY133393A (es)
NO (1) NO20010715L (es)
NZ (1) NZ509778A (es)
PE (1) PE20000952A1 (es)
PL (1) PL346055A1 (es)
PT (1) PT1104422E (es)
SI (1) SI1104422T1 (es)
SK (1) SK2222001A3 (es)
TR (1) TR200100448T2 (es)
TW (1) TWI224598B (es)
WO (1) WO2000009507A1 (es)
YU (1) YU11601A (es)
ZA (1) ZA200101186B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
JP2004523559A (ja) * 2001-02-28 2004-08-05 スミスクライン ビーチャム コーポレーション 過敏性腸症候群および機能性胃腸症の治療方法
EP1418882A1 (en) 2001-08-24 2004-05-19 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PT1444233E (pt) 2001-11-09 2011-09-29 Gilead Palo Alto Inc Antagonistas de receptor de adenosina a2b
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7342006B2 (en) * 2003-08-25 2008-03-11 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US8318728B2 (en) 2008-05-14 2012-11-27 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US20120108614A1 (en) * 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
BRPI0909614A2 (pt) * 2008-05-30 2015-09-22 Hoffmann La Roche "composto, composição farmacêutica, método de tratamento de um transtorno hiperproliferativo em um mamífero, processo para a preparação de uma composição farmacêutica, método para a inibição ou modulação da atividade de quinase de lipídio em um mamífero, kit para o tratamento de condição mediada por pi3k e método de preparação de um composto da fórmula
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
KR20160005365A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
KR20160006762A (ko) 2013-05-10 2016-01-19 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
US9765089B2 (en) * 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2014182943A1 (en) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (es) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
JPH09511220A (ja) * 1993-11-10 1997-11-11 ブリストル‐マイヤーズ スクイブ カンパニー バクテリアによって誘発される炎症性疾患の治療
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
EP0812844B1 (de) 1996-06-07 2002-10-23 Hoechst Aktiengesellschaft Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
AU2640999A (en) 1998-02-26 1999-09-15 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Also Published As

Publication number Publication date
DE69914921T2 (de) 2004-12-23
HK1035195A1 (en) 2001-11-16
AP1408A (en) 2005-05-06
CN1323309A (zh) 2001-11-21
HUP0103637A2 (en) 2002-06-29
NZ509778A (en) 2003-08-29
PE20000952A1 (es) 2000-09-29
BR9913020A (pt) 2001-05-08
ID28723A (id) 2001-06-28
AP2001002071A0 (en) 2001-03-31
US6770267B2 (en) 2004-08-03
TWI224598B (en) 2004-12-01
KR20010085369A (ko) 2001-09-07
CN1251676C (zh) 2006-04-19
US20030032804A1 (en) 2003-02-13
CN1149215C (zh) 2004-05-12
ATE259810T1 (de) 2004-03-15
NO20010715L (no) 2001-04-02
AU5732399A (en) 2000-03-06
ZA200101186B (en) 2002-02-12
EP1104422B1 (en) 2004-02-18
AU775819B2 (en) 2004-08-19
EA200100127A1 (ru) 2001-10-22
MA26673A1 (fr) 2004-12-20
JP2002522542A (ja) 2002-07-23
WO2000009507A1 (en) 2000-02-24
US20040034020A1 (en) 2004-02-19
DK1104422T3 (da) 2004-06-14
PL346055A1 (en) 2002-01-14
EE200100083A (et) 2002-06-17
JP2004137251A (ja) 2004-05-13
CO5130007A1 (es) 2002-02-27
MY133393A (en) 2007-11-30
DE69914921D1 (en) 2004-03-25
US6608069B1 (en) 2003-08-19
JP2004115534A (ja) 2004-04-15
YU11601A (sh) 2004-03-12
IL141318A0 (en) 2002-03-10
EE04721B1 (et) 2006-10-16
EP1104422A1 (en) 2001-06-06
EA004139B1 (ru) 2004-02-26
CA2340350A1 (en) 2000-02-24
GB9817623D0 (en) 1998-10-07
IS5843A (is) 2001-02-09
ES2215399T3 (es) 2004-10-01
PT1104422E (pt) 2004-06-30
SI1104422T1 (en) 2004-06-30
CN1515571A (zh) 2004-07-28
JP3631961B2 (ja) 2005-03-23
NO20010715D0 (no) 2001-02-12
SK2222001A3 (en) 2001-12-03
TR200100448T2 (tr) 2001-09-21
HUP0103637A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
AR020154A1 (es) Derivados de glicol de xantinas, composiciones farmaceuticas, uso en la manufactura de medicamentos, metodos de tratamiento y proceso de preparacion
DK0513104T3 (da) Anvendelse af et alfa-tocopherolphosphat eller et af dets derivater til fremstilling af kosmetiske, dermatologiske eller farmaceutiske præparater, og således opnåede præparater
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
AR034422A1 (es) Una composicion de resina de polipropileno que contiene un derivado de acido trimesico, un metodo para proveer una resina con un valor de niebla menor de 62%, un uso del derivado de acido trimesico como agente reductor de niebla, mezclas que contienen los derivados de acidos trimesicos, composicione
EP0611301A4 (en) CHELATING COMPOSITIONS COMPRISING OXIME COMPOUNDS.
AR035933A1 (es) Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato.
AR017730A1 (es) Compuestos derivados biciclicos del acido hidroxamico, composiciones que los contienen y uso de los mismos para la preparacion de medicamentos
HUP0004076A2 (hu) C-4"-Szubsztituált-makrolid-származékok
DE60018135D1 (de) Benzothiophenderivate, Benzofuranderivate und Indolderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE58908652D1 (de) Aminoalkylindole, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate.
RS49906B (sr) Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova
AR036750A1 (es) Utilizacion de un compuesto de poliguanidina para el tratamiento o el marcado del cabello, en especial el planchado o la permanente
DE69717044T2 (de) Flavone-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
AR045755A1 (es) Una solucion acuosa de agentes blanqueadores fluorescentes y uso de la misma en el blanqueo de fibras textiles y papel.
AR030239A1 (es) Fta lidas substituidas, un procedimiento para su preparacion y composiciones farmaceuticas que contienen las mismas
AR029618A1 (es) Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos
AR035599A1 (es) Compuestos 1,8-naftiridina, dihidroquinolina y piridol[1,2,3-de][1,4]benzoxazina sustituidos, medicamentos, agentes terapeuticos, metodos de produccion y usos en la produccion de un medicamento, de un agente antibacteriano y de un agente para tratar una enfermedad infecciosa
HUP0303636A2 (hu) Dihidronaftalin-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
ATE107298T1 (de) 3-aminochroman-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JP2006517932A5 (es)
DE68921719D1 (de) Amphotericin B Derivate.
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DE69106323D1 (de) Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen.
HUP0301000A2 (hu) 2-Aminotiazolin-származékok, eljárás előállításukra, a vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk NO-szintáz inhibitorokként
EA200100725A2 (ru) Новые бензотиадиазиновые соединения, способ их получения и их содержащие фармацевтические композиции

Legal Events

Date Code Title Description
FA Abandonment or withdrawal